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Abstract
Background: Metastatic malignancy to the thyroid gland is generally uncommon due to an
unfavourable local thyroid micro-environment which impairs the ability of metastatic cells to settle
and thrive. Metastases to the thyroid gland have however been reported to occur occasionally
particularly if there has been disruption to normal thyroid tissue architecture.
Case presentation: We report a patient with a history of surgically resected rectal
adenocarcinoma who presents with a rising serum CEA level and an 18F-FDG PET scan positive
thyroid nodule which was subsequently confirmed at surgery to be a focus of metastatic rectal
adenocarcinoma within a primary poorly differentiated papillary thyroid carcinoma.
Subsequent treatment involved right hemi-thyroidectomy, pulmonary wedge resection of
oligometastatic metastatic colorectal cancer and chemotherapy.
Conclusion: Metastatic rectal carcinoma to the thyroid gland and in particular to a primary
thyroid malignancy is rare and unusual. Prognosis is likely to be more dependent on underlying
metastatic disease rather than the primary thyroid malignancy hence primary treatments should be
tailored towards treating and controlling metastatic disease and less emphasis placed on the
primary thyroid malignancy.
Background
Metastatic malignancy to the thyroid gland, although con-
sidered rare, occurs more frequently than expected. Micro-
scopic metastases to the thyroid gland have been reported
to occur in 4%–9% of autopsy studies[1,2], with breast,
lung, melanoma and kidney the most common primary
malignancies. Metastatic colorectal cancer to the thyroid
gland is considered unusual, with 33 previous cases
reported in the literature up till 2008 [3-6]. There are no
previously published reports of metastatic malignancy to
a primary thyroid malignancy.
Case presentation
A 52 year old man with a history of T3N1M0 (Dukes C)
rectal adenocarcinoma treated with neo-adjuvant chemo-
radiotherapy (5FU + radiotherapy) followed by anterior
resection and adjuvant chemotherapy (5FU) presented 18
months post completion of therapy with rising serum
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nancy to 9.7 μg/l) and a 15 mm left lower lobe pulmonary
nodule on computerized tomography (CT), suggestive of
a metastatic deposit (figure 1). He had no other significant
past medical history and no family history of malignancy.
Physical examination was unremarkable, with no obvious
mass lesions in the abdomen or palpable local recurrence
in the rectal stump.
An 18F-FDG whole body Positron Emission Tomography
(PET) scan was performed to further evaluate the nature of
the left lower lobe pulmonary nodule and to evaluate any
other possible sites of metastatic disease. The whole body
PET scan demonstrated significant 18F-FDG uptake in the
left lower lobe pulmonary nodule compatible with a met-
astatic deposit (figure 2). An intensely FDG-avid right
lower lobe thyroid nodule was also noted, which corre-
sponded with a large partially calcified well circumscribed
nodule on CT.
An ultrasound guided fine needle aspirate of the right
lower pole thyroid nodule was performed which revealed
malignant cells with features suggestive of a primary pap-
illary thyroid cancer. A right hemi-thyroidectomy was
subsequently performed. Macroscopically, the resected
thyroid specimen demonstrated a well-circumscribed
dominant thyroid nodule measuring 32 mm in diameter
with a pale tan capsule less than 1 mm in thickness. The
cut surface had a variegated appearance with pale tan fria-
ble tissue intermixed with foci of yellow tissue and dark
brown foci. Histological examination revealed cells typi-
cal of metastatic adenocarcinoma of the colon intermixed
CT scan demonstrating 4.3 × 2.5 cm partially calcified complex dominant nodule in the inferior pole of the right lobe of thyroidFigure 1
CT scan demonstrating 4.3 × 2.5 cm partially calcified complex dominant nodule in the inferior pole of the 
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roid carcinoma (figure 3).
A wedge resection of the left lower lobe pulmonary nod-
ule was subsequently performed which confirmed meta-
static colorectal adenocarcinoma (figure 4). Serum CEA
level normalized post operatively (1.9 μg/l) and no fur-
ther surgery was contemplated. Despite no further overt
metastatic disease on CT, the patient was commenced on
a course of chemotherapy (5 FU/Oxaliplatin) to treat pre-
sumed low volume metastatic colorectal disease and thus
decrease the risk of developing overt recurrence. No fur-
ther thyroid cancer specific treatment has been initiated.
Discussion
Metastatic lesions to the thyroid gland are generally con-
sidered rare, possibly due to a high oxygen and iodine
environment which may impair the ability of metastatic
18F-FDG PET/CT scan demonstrating focal intense 18F-FDG uptake in the nodule in the inferior pole of the right lobe of thy-roidFigure 2
18F-FDG PET/CT scan demonstrating focal intense 18F-FDG uptake in the nodule in the inferior pole of the 
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flow through the thyroid gland also possibly plays a role
in impeding the ability for metastatic cells to gain a foot-
hold[3]. Perhaps unsurprisingly, when primary thyroid
pathology occurs which results in structural change, this
has been associated with an increased incidence of metas-
tases to the thyroid gland. Multinodular goiters and ade-
nomatous change have both been associated with an
increased incidence of metastases to the thyroid gland[7].
It is possible our patient had a pre-existing primary thy-
roid carcinoma at the time of initial surgery for the pri-
mary rectal malignancy which altered the local thyroid
environment rendering conditions more favorable for
metastatic rectal adenocarcinoma cells to settle.
With the advent of improved diagnostic imaging technol-
ogy such as 18F-FDG PET, an increasing number of inci-
dental cases of metastatic disease to the thyroid gland are
likely to be detected. Well differentiated primary thyroid
carcinomas such as papillary and follicular carcinomas are
generally not 18F-FDG avid on PET scanning and usually
only become 18F-FDG avid if they de-differentiate.
It has been reported in the literature incidentally PET
detected 18F-FDG avid primary thyroid malignancies are
generally a more aggressive variant of primary thyroid
cancer which harbour a higher rate of unfavourable prog-
nostic factors and are often less well differentiated[8]. In
our case, the coexistent focus of metastatic colorectal ade-
nocarcinoma within a primary poorly differentiated thy-
roid cancer somewhat complicates the issue, as both
tumours are likely to be 18F-FDG avid.
To our knowledge there have been no cases of metastatic
malignancy within a primary thyroid malignancy
reported previously in the literature. As such, there is scant
evidence in the literature regarding the most appropriate
management strategy for such a patient. Conventional
management of a primary thyroid malignancy usually
involves total surgical thyroidectomy followed by radioio-
dine therapy to ablate the thyroid remnant, decrease risk
of recurrence and enable adequate follow up using I-131
whole body scintigraphy and stimulated thyroglobulin
levels [9-13].
In our case, prognosis is more likely to be dependent on
the patient's metastatic rectal adenocarcinoma rather than
the primary thyroid malignancy. Stage IV metastatic rectal
adenocarcinoma portends a poor prognosis, with five year
survival rates of between 4%–8%[14,15]. More specific to
our case, in a review of 12 patients with metastatic rectal
carcinoma to the thyroid between 1990 to 1993 by Fujita
et al [3], in the one patient without metastases to any
other organ but the thyroid, survival was just 4 years. Pri-
Histological examination of the thyroid nodule revealed (A) poorly d ffer ntiated primary papillary thyroid carcinoma inte mixed with (B) foci of met static rectal adenocarcinoma  H&E Low power ×10 i H&E High Powe  ×20Figure 3
Histological examination of the thyroid nodule 
revealed (A) poorly differentiated primary papillary 
thyroid carcinoma intermixed with (B) foci of meta-
static rectal adenocarcinoma i H&E Low power ×10 ii 
H&E High Power ×20.
Histological examination of the resected pulmonary nodule revea ed (B) metast c rectal ad no arcino a i  a back-ground of (C) normal lung par nchymaFig r  4
Histological examination of the resected pulmonary 
nodule revealed (B) metastatic rectal adenocarci-
noma in a background of (C) normal lung paren-
chyma. H&E High Power ×20.Page 4 of 5
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mary early stage non anaplastic thyroid carcinoma even if
poorly differentiated has a better prognosis compared to
metastatic rectal cancer. Poorly differentiated primary fol-
licular thyroid carcinoma has been reported to have a 5
year survival rate of 63% in a recent published series of 40
patients[16].
As a result, the primary treatment focus in our patient was
tailored towards treating metastatic rectal carcinoma and
less so the primary thyroid malignancy. It is also of note,
many poorly differentiated thyroid carcinomas are not
particularly radioiodine avid and it is quite possible the
impact of radioiodine therapy on reducing recurrence
rates may be greatly diminished in this setting.
Conclusion
Metastatic rectal carcinoma to the thyroid gland and in
particular to a primary thyroid malignancy is uncommon
and to our knowledge has not been reported. Prognosis is
likely to be more dependent on underlying metastatic dis-
ease rather than the primary thyroid malignancy hence
primary treatments should be tailored towards treating
and controlling metastatic disease and less emphasis
placed on the primary thyroid malignancy.
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